4//SEC Filing
ABERNETHY MATT 4
Accession 0000914475-24-000170
CIK 0000914475other
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 4:45 PM ET
Size
9.0 KB
Accession
0000914475-24-000170
Insider Transaction Report
Form 4
ABERNETHY MATT
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-07-16$73.60/sh+900$66,240→ 32,428 total - Sale
Common Stock
2024-07-16$150.04/sh−900$135,037→ 31,528 total - Exercise/Conversion
Non-Qualified Stock Option
2024-07-16−900→ 14,100 totalExercise: $73.60Exp: 2027-12-01→ Common Stock (900 underlying)
Footnotes (3)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning January 1, 2019.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001724097
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 4:45 PM ET
- Size
- 9.0 KB